Ocrelizumab (Ocrevus®) is an intravenously administered, humanized anti-CD20
monoclonal antibody approved for the treatment of adults with relapsing forms of multiple …

Background Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central
nervous system. The treatment of MS has always been a focus of neurological research. To …

Background: The Association of British Neurologists (ABN) 2015 guidelines suggested
classifying multiple sclerosis therapies according to their average relapse reduction. We …

Aim: To compare the efficacy of ofatumumab to other disease-modifying therapies (DMTs)
for relapsing multiple sclerosis (RMS). Materials & methods: A network meta-analysis was …

Background Currently, 19 disease-modifying therapies (DMTs) have been approved for the
treatment of patients with relapsing forms of multiple sclerosis (RMS). Objective The …

Aim: To assess the relative efficacy of disease-modifying therapies (DMTs) for relapsing
multiple sclerosis (RMS) including newer therapies (ozanimod, ponesimod, ublituximab) …

Objective Cladribine tablets were tested against placebo in randomized controlled trials
(RCTs). In this study, the effectiveness of cladribine vs other approved drugs in patients with …

Extending the natalizumab interval after the 24th administration could reduce the risk of
progressive multifocal leukoencephalopathy (PML). The objective is to evaluate the …

Objective This study aimed to compare the safety profile of high-efficacy disease-modifying
therapies (DMTs) natalizumab, fingolimod, alemtuzumab, cladribine, ocrelizumab …

Aim We recently proposed miR‐142‐3p as a molecular player in inflammatory synaptopathy,
a new pathogenic hallmark of multiple sclerosis (MS) and of its mouse model experimental …